Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171086
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Torres Martí, Antoni | - |
dc.contributor.author | Bassetti, Matteo | - |
dc.contributor.author | Welte, Tobias | - |
dc.contributor.author | Rivolo, Simone | - |
dc.contributor.author | Remak, Edit | - |
dc.contributor.author | Peral, Carmen | - |
dc.contributor.author | Charbonneau, Claudie | - |
dc.contributor.author | Hammond, Jennifer | - |
dc.contributor.author | Ansari, Wajeeha | - |
dc.contributor.author | Grau, Santiago | - |
dc.date.accessioned | 2020-10-07T09:35:56Z | - |
dc.date.available | 2020-10-07T09:35:56Z | - |
dc.date.issued | 2019-10-31 | - |
dc.identifier.issn | 0899-7764 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171086 | - |
dc.description.abstract | Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS).Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature.Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Taylor and Francis | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1080/13696998.2019.1688819 | - |
dc.relation.ispartof | Journal of Media Economics, 2019, vol. 23, num. 2, p. 148-155 | - |
dc.relation.uri | https://doi.org/10.1080/13696998.2019.1688819 | - |
dc.rights | cc-by-nc-nd (c) Torres et. al. , 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Pneumònia adquirida a la comunitat | - |
dc.subject.classification | Antibiòtics | - |
dc.subject.other | Community-acquired pneumonia | - |
dc.subject.other | Antibiotics | - |
dc.title | Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 700167 | - |
dc.date.updated | 2020-10-07T09:35:56Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
700167.pdf | 1.71 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License